ARC LEADERSHIP

 

 
 

The members of the ARC leadership team are deeply committed to working together to improve outcomes for amyloidosis patients.

These exceptional individuals have been instrumental in creating and driving the ARC’s excellent programs, making a difference for all types of systemic amyloidosis.


Leadership

 
  Isabelle Lousada President & CEO

 

Isabelle Lousada

President & CEO

 
  Giampaolo Merlini, MD Director of the Center for Research and Treatment of Systemic Amyloidosis, and of the Biotechnology Research Laboratories, Scientific Institute Policlinico San Matteo, University of Pavia, Italy 

 

Giampaolo Merlini, MD

Director of the Center for Research and Treatment of Systemic Amyloidosis, and of the Biotechnology Research Laboratories, Scientific Institute Policlinico San Matteo, University of Pavia, Italy 

  Raymond Comenzo, MD Director, Blood Bank and Stem Cell Processing Laboratory; Professor, Tufts University School of Medicine 

 

Raymond Comenzo, MD

Director, Blood Bank and Stem Cell Processing Laboratory; Professor, Tufts University School of Medicine 

 
  Dena Heath Northern California Amyloidosis Support Group Facilitator

 

Dena Heath

Northern California Amyloidosis Support Group Facilitator

 
  Eric Low OBE CEO Myeloma UK

 

Eric Low OBE

CEO Myeloma UK

  Sarah Cairns-Smith Senior Partner and Managing Director Boston Consulting Group

 

Sarah Cairns-Smith

Senior Partner and Managing Director Boston Consulting Group

 

Steering Committee

A multidisciplinary team of experts in the field of amyloidosis oversees the ARC’s scientific agenda and strategic direction.

Angela Dispenzieri MD, Mayo Clinic

Raymond Comenzo MD, Tufts Medical School

Eric Low OBE, Myeloma UK

Jeffery Kelly PhD, Scripps Research Institute

Mathew Maurer MD, New York-Presbyterian Hospital

Giampaolo Merlini MD, University of Pavia

Vaishali Sanchorawala MD, Boston Medical Center

Ashutosh Wechalekar MD, Royal Free Hospital